Simulect (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the Simulect drug offered from Novartis Pharmaceuticals Corporation. This Interleukin 2 Receptor Antagonists [MoA],Interleukin 2 Receptor-directed Antibody Interactions [MoA],Interleukin-2 Receptor Blocking Antibody [EPC] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
| NON-PROPRIETARY NAME: | basiliximab |
| SUBSTANCE NAME: | BASILIXIMAB |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Interleukin 2 Receptor Antagonists [MoA],Interleukin 2 Receptor-directed Antibody Interactions [MoA],Interleukin-2 Receptor Blocking Antibody [EPC] |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | INJECTION, POWDER, FOR SOLUTION |
| MARKETING CATEGORY NAME: | BLA |
| START MARKETING DATE: | 1998-05-12 |
| END MARKETING DATE: | 0000-00-00 |
Simulect HUMAN PRESCRIPTION DRUG Details:
| Item Description | Simulect from Novartis Pharmaceuticals Corporation |
| LABELER NAME: | Novartis Pharmaceuticals Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 20(mg/5mL) |
| START MARKETING DATE: | 1998-05-12 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 0078-0331_88e1d8f7-be69-4d69-b417-0125a8a6b4b9 |
| PRODUCT NDC: | 0078-0331 |
| APPLICATION NUMBER: | BLA103764 |
Other BASILIXIMAB Pharmaceutical Manufacturers / Labelers:
